Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Case reports in medicine

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G.
PMID: 27504122
Case Rep Med. 2016;2016:9639585. doi: 10.1155/2016/9639585. Epub 2016 Jul 18.

Indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) inhibits T-cell activation and promotes T-cell differentiation into regulatory T-cells. Moreover, IDO expression promotes resistance to immunotherapies targeting immune checkpoints such as the cytotoxic T lymphocyte antigen-4 (CTLA-4). Here, a patient...

Cite
Sioud M, Nyakas M, Sæbøe-Larssen S, et al. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Rep Med. 2016;2016:9639585doi: 10.1155/2016/9639585.
Sioud, M., Nyakas, M., Sæbøe-Larssen, S., Mobergslien, A., Aamdal, S., & Kvalheim, G. (2016). Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case reports in medicine, 20169639585. https://doi.org/10.1155/2016/9639585
Sioud, Mouldy, et al. "Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine." Case reports in medicine vol. 2016 (2016): 9639585. doi: https://doi.org/10.1155/2016/9639585
Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Rep Med. 2016;2016:9639585. doi: 10.1155/2016/9639585. Epub 2016 Jul 18. PMID: 27504122; PMCID: PMC4967686.
Copy Download .nbib Format: NLM
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells.

Molecular therapy. Methods & clinical development

Sioud M, Westby P, Olsen JK, Mobergslien A.
PMID: 26605373
Mol Ther Methods Clin Dev. 2015 Nov 04;2:15043. doi: 10.1038/mtm.2015.43. eCollection 2015.

Antibody-dependent cellular cytotoxicity (ADCC), a key effector function for the clinical effectiveness of monoclonal antibodies, is triggered by the engagement of the antibody Fc domain with the Fcγ receptors expressed by innate immune cells such as natural killer (NK)...

Cite
Sioud M, Westby P, Olsen JK, et al. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Mol Ther Methods Clin Dev. 2015;2:15043doi: 10.1038/mtm.2015.43.
Sioud, M., Westby, P., Olsen, J. K., & Mobergslien, A. (2015). Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Molecular therapy. Methods & clinical development, 215043. https://doi.org/10.1038/mtm.2015.43
Sioud, Mouldy, et al. "Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells." Molecular therapy. Methods & clinical development vol. 2 (2015): 15043. doi: https://doi.org/10.1038/mtm.2015.43
Sioud M, Westby P, Olsen JK, Mobergslien A. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Mol Ther Methods Clin Dev. 2015 Nov 04;2:15043. doi: 10.1038/mtm.2015.43. eCollection 2015. PMID: 26605373; PMCID: PMC4632835.
Copy Download .nbib Format: NLM
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.

Journal for immunotherapy of cancer

Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, Berndt S, Zitzmann-Kolbe S, Kamfenkel C, Stargard S, Hammer S, Jørgensen JS, Jackerott M, Nielsen CH, Schatz CA, Hennekes H, Karlsson J, Cuthbertson AS, Mumberg D, Hagemann UB.
PMID: 34615703
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002387.

BACKGROUND: Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to-repair clustered DNA double-strand breaks. However, thus far, their effects on the immune system are...

Cite
Lejeune P, Cruciani V, Berg-Larsen A, et al. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. J Immunother Cancer. 2021;9(10)doi: 10.1136/jitc-2021-002387.
Lejeune, P., Cruciani, V., Berg-Larsen, A., Schlicker, A., Mobergslien, A., Bartnitzky, L., Berndt, S., Zitzmann-Kolbe, S., Kamfenkel, C., Stargard, S., Hammer, S., Jørgensen, J. S., Jackerott, M., Nielsen, C. H., Schatz, C. A., Hennekes, H., Karlsson, J., Cuthbertson, A. S., Mumberg, D., & Hagemann, U. B. (2021). Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. Journal for immunotherapy of cancer, 9(10), . https://doi.org/10.1136/jitc-2021-002387
Lejeune, Pascale, et al. "Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy." Journal for immunotherapy of cancer vol. 9,10 (2021). doi: https://doi.org/10.1136/jitc-2021-002387
Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, Berndt S, Zitzmann-Kolbe S, Kamfenkel C, Stargard S, Hammer S, Jørgensen JS, Jackerott M, Nielsen CH, Schatz CA, Hennekes H, Karlsson J, Cuthbertson AS, Mumberg D, Hagemann UB. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002387. PMID: 34615703; PMCID: PMC8496392.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries